
|Videos|June 2, 2015
Adding Palbociclib Delays Progression in HR-Positive Breast Cancer
Author(s)Nicholas C. Turner, MD
In this video we discuss the results of the PALOMA3 trial, which tested fulvestrant and palbociclib in metastatic, hormone receptor–positive HER2-negative breast cancer.
Advertisement
In this video, Nicholas C. Turner, MD, of Royal Marsden Hospital and the Cancer Research Institute in London, discusses the results of the PALOMA3 trial, which tested fulvestrant and palbociclib in metastatic, hormone receptor (HR)-positive HER2-negative breast cancer.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
Modifiable Risk Factors Suggest Potential for Improving Cancer Prevention
2
Barriers to CAR T-Cell Referral and Center Access in Multiple Myeloma
3
2026 Tandem Meetings: What’s the Latest Research in Multiple Myeloma?
4
Exploring The Impact of ADTs on Cardiac Risk in Prostate Cancer Treatment
5




































